Skip to main content

Table 2 Frequency of the autoantibodies assessed before therapy and at different times after initiation of infliximab treatment

From: Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

Antibody Positivity (n [%]) P valuea
  Before therapy From start of infliximab treatment  
   30 weeks 54 weeks 78 weeks  
ANA 15/30 (50) 21/30 (70) 23/30 (76.7) 24/30 (80) 0.0292
Anti-dsDNA (ELISA) 2/30 (6.7) 3/30 (10) 5/30 (16.7) 0/30 (0) 0.4915
Anti-dsDNA (IIF) 1/30 (3.3) 1/30 (3.3) 2/3 (6.7) 1/30 (3.3) -
Anti-ENAb 3/30 (10) 4/30 (13.3) 4/30 (13.3) 4/30 (13.3) 0.999
aCL IgG 0/30 (0) 1/30 (3.3) 2/30 (6.7) 2/30 (6.7) 0.4915
aCL IgM 0/30 (0) 1/30 (3.3) 2/30 (6.7) 3/30 (10) 0.2373
ANCA 0/30 (0) 0/30 (0) 0/30 (0) 0/30 (0) -
RF 26/30 (86.7) 27/30 (90) 25/30 (83.3) 24/30 (80) 0.7306
Anti-CCP 25/30 (83.3) 22/30 (73.3) 22/30 (73.3) 25/30 (83.3) -
EMA (IIF) 0/30 (0) 0/30 (0) 0/30 (0) 0/30 (0) -
  1. aComparison between 0 and 78 weeks. bOnly anti-SSA(Ro) reactivity was found. ACL, anticardiolipin; ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; CCP, cyclic citrullinated peptide; DAS 28, Disease Activity Score; ds, double-stranded; ELISA, enzyme-linked immunosorbent assay; EMA, antiendomysial antibody; ENA, extractable nuclear antigen; IIF, indirect immunofluorescence; RF, rheumatoid factor.